Investment Analysts’ Weekly Ratings Updates for Tilray (TLRY)

A number of firms have modified their ratings and price targets on shares of Tilray (NASDAQ: TLRY) recently:

  • 6/17/2019 – Tilray had its price target lowered by analysts at Compass Point from $41.00 to $38.00. They now have a “sell” rating on the stock.
  • 6/10/2019 – Tilray is now covered by analysts at Compass Point. They set a “neutral” rating and a $41.00 price target on the stock.
  • 6/5/2019 – Tilray is now covered by analysts at Stifel Nicolaus. They set a “hold” rating and a $37.00 price target on the stock.
  • 6/4/2019 – Tilray is now covered by analysts at Oppenheimer Holdings Inc.. They set a “market perform” rating on the stock.
  • 5/21/2019 – Tilray was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Tilray, Inc. is a pharmaceutical company. It develops cannabis based medicines, drugs, drops and oil products. Tilray, Inc. is based in NANAIMO, Canada. “
  • 5/15/2019 – Tilray had its price target lowered by analysts at Piper Jaffray Companies from $84.00 to $72.00. They now have an “overweight” rating on the stock.
  • 5/15/2019 – Tilray was upgraded by analysts at BMO Capital Markets from an “underperform” rating to a “market perform” rating. They now have a $50.58 price target on the stock.
  • 5/13/2019 – Tilray is now covered by analysts at Alliance Global Partners. They set a “neutral” rating and a $50.00 price target on the stock.
  • 5/3/2019 – Tilray was upgraded by analysts at Jefferies Financial Group Inc from an “underperform” rating to a “hold” rating. They now have a $57.00 price target on the stock, down previously from $61.00.
  • 4/29/2019 – Tilray had its price target lowered by analysts at Piper Jaffray Companies from $90.00 to $84.00. They now have an “overweight” rating on the stock.
  • 4/25/2019 – Tilray was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Tilray, Inc. is a pharmaceutical company. It develops cannabis based medicines, drugs, drops and oil products. Tilray, Inc. is based in NANAIMO, Canada. “

TLRY opened at $49.71 on Friday. The company has a quick ratio of 2.06, a current ratio of 2.35 and a debt-to-equity ratio of 1.13. The company has a market cap of $4.42 billion and a P/E ratio of -60.62. Tilray Inc has a fifty-two week low of $20.10 and a fifty-two week high of $300.00.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). The business had revenue of $23.00 million for the quarter, compared to the consensus estimate of $20.50 million. Tilray had a negative return on equity of 43.71% and a negative net margin of 159.09%. Tilray’s revenue for the quarter was up 194.9% compared to the same quarter last year. On average, equities research analysts anticipate that Tilray Inc will post -0.89 earnings per share for the current fiscal year.

In related news, insider Brendan Kennedy sold 106,109 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $63.44, for a total transaction of $6,731,554.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Castaneda sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $51.72, for a total transaction of $517,200.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 166,109 shares of company stock valued at $10,409,698. 3.40% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of TLRY. Advisors Asset Management Inc. purchased a new stake in Tilray in the 4th quarter valued at approximately $224,000. Janney Montgomery Scott LLC purchased a new stake in Tilray in the 4th quarter valued at approximately $354,000. Toronto Dominion Bank purchased a new stake in Tilray in the 4th quarter valued at approximately $27,000. LPL Financial LLC lifted its stake in Tilray by 57.2% in the 4th quarter. LPL Financial LLC now owns 7,732 shares of the company’s stock valued at $545,000 after buying an additional 2,814 shares in the last quarter. Finally, California Public Employees Retirement System lifted its stake in Tilray by 247.4% in the 4th quarter. California Public Employees Retirement System now owns 5,617 shares of the company’s stock valued at $396,000 after buying an additional 4,000 shares in the last quarter. 2.10% of the stock is owned by hedge funds and other institutional investors.

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Read More: Short Selling Stocks, A Beginner’s Guide

Receive News & Ratings for Tilray Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Inc and related companies with MarketBeat.com's FREE daily email newsletter.